Progressive Metastatic Castrate Resistant Prostate Cancer

Oncology

Prevalence

256.0 / 100K

Incidence

111.0 / 100K/yr

22 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Phase 2(1)

Drug	Company
JSB462 Dose 1 QD	Novartis AG (NVS)

Phase 1(6)

Drug	Company
JSB462 QD	Merus N.V. (MRUS)
Tulmimetostat DL1 QD	Merus N.V. (MRUS)
Tulmimetostat DL2 QD	Merus N.V. (MRUS)
Tulmimetostat DL3 QD	Merus N.V. (MRUS)
Tulmimetostat Doses 1 or 2 QD	Merus N.V. (MRUS)
Tulmimetostat RP2D QD	Merus N.V. (MRUS)

Phase 1/Phase 2(15)

Drug	Company
jsb462 dose 1 qd	Novartis AG (NVS)
jsb462 dose 2 qd	Novartis AG (NVS)
JSB462 Dose 2 QD	Novartis AG (NVS)
jsb462 qd	Novartis AG (NVS)
JSB462 QD	Novartis AG (NVS)
tulmimetostat dl1 qd	Novartis AG (NVS)
Tulmimetostat DL1 QD	Novartis AG (NVS)
tulmimetostat dl2 qd	Novartis AG (NVS)
Tulmimetostat DL2 QD	Novartis AG (NVS)
tulmimetostat dl3 qd	Novartis AG (NVS)
Tulmimetostat DL3 QD	Novartis AG (NVS)
tulmimetostat doses 1 or 2 qd	Novartis AG (NVS)
Tulmimetostat Doses 1 or 2 QD	Novartis AG (NVS)
tulmimetostat rp2d qd	Novartis AG (NVS)
Tulmimetostat RP2D QD	Novartis AG (NVS)

Compare drugs

JSB462 Dose 1 QD vs JSB462 QD JSB462 Dose 1 QD vs Tulmimetostat DL1 QD JSB462 Dose 1 QD vs Tulmimetostat DL2 QD

Frequently asked questions

How many drugs are in development for Progressive Metastatic Castrate Resistant Prostate Cancer?

BioSniper tracks 22 drugs in development for Progressive Metastatic Castrate Resistant Prostate Cancer across 2 companies.

How many clinical trials target Progressive Metastatic Castrate Resistant Prostate Cancer?

There are 1 clinical trial targeting Progressive Metastatic Castrate Resistant Prostate Cancer tracked by BioSniper.

What is the prevalence of Progressive Metastatic Castrate Resistant Prostate Cancer?

The estimated prevalence of Progressive Metastatic Castrate Resistant Prostate Cancer is approximately 256.0 per 100,000 population.

Deep-dive into Progressive Metastatic Castrate Resistant Prostate Cancer

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Progressive Metastatic Castrate Resistant Prostate Cancer — Drugs in Development & Clinical Trials | BioSniper